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Abstract  
 
Introduction: Decision-analytic modelling (DAM) has been increasingly used to aid decision making in 
healthcare. The growing use of modelling in economic evaluations has led to increased scrutiny of the methods 
used. 
 
Aim: To perform a systematic review to identify and critically assess good practice guidelines, with particular 
emphasis on contemporary developments. 
 
Methods: A systematic review of English language articles was undertaken to identify papers presenting 
guidance for good practice in DAM in the evaluation of healthcare. The inclusion criteria were: papers 
providing guidance or criteria against which to assess good practice in DAM and studies providing criteria or 
elements for good practice in some areas of DAM. The review covered the period January 1990 to March 2014 
and included the following electronic bibliographic databases: Cochrane Library; Cochrane Methodology 
Register and HTA; NHS EED; MEDLINE and PubMed (Embase). Additional studies were identified by 
searching references.  
 
Results: 33 papers were included in this review. A practical five-dimension framework was developed which 
describe the key elements of good research practice that should be considered and reported to increase the 
credibility of the results obtained from DAM in the evaluation of healthcare. 
 
Discussion: This study is the first to critically review all available guidelines and statements of good practice in 
DAM since 2006. The development of good practice guidelines is an ongoing process and important efforts 
have been made to identify what is good practice and to keep these guidelines up-to-date.  
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Key points for decision makers  
 
 This study is the first, since 2006, to critically review available guidelines in DAM  
 A dramatic evolution of good practice guidelines for DAM was found accompany with important efforts to 
keep these guidelines up-to date, functional and helpful 
 This study proposes a practical framework to serve as a reference point towards the thorough consultation 
of good practice guidelines. 
 This study did not review guidelines in light of current practice, which may be seen as a limitation; further 
research is required to assess the adherence of current practice to guidelines  
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1. Introduction 
DAM in health care has been widely used to synthesize clinical and economic evidence and to inform resource 
allocation decisions for the purpose of allowing scarce health care resources to be allocated more efficiently (1). 
In simple terms, in DAM, a model is structured to represent clinical pathways to examine whether an 
intervention, compared for example to current practice, is cost effective (2). Building a model requires 
consideration of important elements including the complexity of the clinical area; the available evidence related 
to the disease; as well as other issues such as the scope or boundaries of the model; the appropriate time horizon; 
the perspective of the analysis; the availability of data and a formal synthesis of evidence within the model (2, 
3). The increasing use of DAM in the economic evaluation of health care interventions and health technology 
assessments requires the use of sound analytic methods and consideration of the requirements of good practice.  
The aim of this study was to perform a review to identify and critically assess good practice guidelines, 
highlighting areas where these have failed to provide recommendations, with emphasis being given to more 
recent developments. In this study we define DAM as a method that “uses mathematical relationships to define a 
series of possible consequences that would flow from a set of alternative options being evaluated” (4) (p.6).  
2. Methods 
 
A systematic review of articles written in English was undertaken with the aim of identifying published 
guidelines on DAM in healthcare. The following types of studies were included: guidelines for DAM or Health 
Technology Assessments (HTA) and other published papers on good practice in DAM. On the basis of an 
assessment of their title and abstract (if available), papers were deemed potentially relevant for inclusion if they: 
1) provided general guidance in DAM for health care or health technology assessment (HTA); or 2) provided 
general criteria against which to assess good practice in DAM (for example a checklist).  
 
This review excluded guidelines on: 1) trials or economic evaluations alongside clinical trials; 2) other non-
DAM studies including statistical or econometric models; and 3) conference abstracts or other non-DAM 
papers. 
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2.1. Search strategy  
 
An initial exploratory approach was undertaken using search terms used in a previous review (5) and this helped 
inform the final search terms used in this review (see Supplemental Material, Appendix 1, Tables 1 and 2). 
Relevant literature was also obtained by checking the references of the included articles.  
 
The following bibliographic databases were searched: The Cochrane Library, Cochrane Methodology Register 
(CMR), Cochrane Health Technology Assessments, NHS Economic Evaluation Database, Embase, and 
MEDLINE. To avoid duplication, the PROSPERO database of prospectively registered systematic reviews in 
health and social care was searched for any existing or ongoing reviews that addressed similar topics, and none 
were identified. This review covered the period from January 1990 to March 2014. This is a period that reflects 
the development of guidelines for DAM in healthcare and the consolidation of good practice guidelines.  
  
2.2. Selection of papers for review 
 
Titles and abstracts (if available) were screened against the inclusion criteria to identify potentially relevant 
papers. In total, 33 studies, corresponding to general guidance or elements of good practice in DAM were 
included in this review. A flow chart showing the study selection process is shown in Figure 1. The 
methodological quality of the papers included in this study was not comprehensively assessed using formal 
checklists due to the diversity of the literature included and the nature of the review. 
 
2.2.1. Data extraction 
 
All studies were manually searched and data were extracted by the first author from each paper using a data 
extraction form. The data extraction form was developed to retrieve and organise information from each paper 
based on its main topic, model structure, model uncertainty, model transparency, and validation. The data 
extraction form was developed through a process in which the content of the papers informed the “areas” that 
the data were extracted under. This approach was utilised to ensure that the review did not miss any information 
related to the model building process. The data was extracted as free text and in the form of a ‘yes/no’ response.  
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3. Results 
 
The DAM guidelines identified in this study have responded to the need to: reflect on how good practice in the 
field has been defined; the need to keep pace with the rapid progress in the way that economic evaluation 
methodology has progressed since the 1980s; and as a means to ensure that guidelines for good practice remain 
current, effective, and helpful. More comprehensive guidelines, for example Philips (5) or the set of the 
International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision 
Making (ISPOR-SMDM) guidelines have been developed as part of bigger projects i.e., a Health Technology 
Assessment project involving experts from prestigious academic institutions or as part of a ‘task force’ 
respectively (see section 3.1).  
 
Recommendations and statements of good practice have been proposed following the application of different 
methods, for example: Philips’ synthesized good practice guidance and accompanying checklist resulted after 
taking each theme and subtheme identified in a systematic review of guidelines followed by technical 
discussions among the research team of its relevance in relation to the development of general guidelines (5). 
Guidelines produced by ISPOR-SMDM resulted from a ‘task force’ consisting of expert developers and 
experienced users of models from academia, industry, and government, with representation from many 
countries. A decision was made to divide the DAM topic into six components and working groups respectively; 
three of these groups covered aspects relevant to all models such as the conceptualization of a model, the 
estimation of model parameters and handling of uncertainty, and the validation of models and issues of 
transparency. The other three components considered specific techniques: state-transition modelling, discrete 
event simulation, and dynamic transmission models. The working groups produced draft reports for each 
section, and in contrast to Philips there was no systematic attempt to review the literature. The first draft of 
recommendations represented the opinions of the experts in the Task Force and these were posted on the ISPOR 
and SMDM Web sites for comment by the general membership of the societies. A second group of experts—
again, with broad representation of modellers and users of models—was invited to formally review the articles. 
Their comments were addressed and after receiving any additional comments and considering any further 
revisions, the final version of each article was prepared and released to the public (see section 3.1).     
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Of the 33 papers included in this review, 15 studies provided general guidelines for good practice or criteria in 
the form of a checklist. Eighteen papers were focused on particular elements of good practice, for example, 
model structure or uncertainty, or model transparency and validation. 
 
 
3.1. Elements of good practice for DAM 
 
Fifteen studies provided general guidelines for good practice; eight out of the 15 guidelines were released before 
2012; (5-13) with the remainder making up the ISPOR-SMDM (14-20) set of guidelines. Tables 1a to 1c present 
a breakdown of the elements of good practice by the main themes of the guidance, i.e., model structure, 
identifying and synthesizing evidence, and model validity. These studies provided a source of complete 
information on the various stages that need to be covered in DAM. Some of the studies constituted a list of 
topics that need to be checked, or questions that modellers need to answer prior to constructing a model. Most 
commonly, guidelines have been presented as a series of good practice statements, starting with Weinstein (13), 
then Philips (5, 9) and more recently ISPOR-SMDM (14-20). DAM guidelines provide a set of principles that 
might lead, for example, to an appropriate model structure or else indicators of areas that require consideration 
in decision modelling (9).  
 
To inform model construction and increase model credibility and validity, these guidelines provide a set of 
principles, checklists, or have stated the agreement of a common application (8, 10-12, 15-17, 19, 20). For 
example, guidelines have stated that model construction is likely to be influenced by the adoption of simplifying 
assumptions reflecting issues such as data availability, and that the design of a model should not be driven by 
the data at hand. Under these circumstances the identification of the explicit characteristics of the disease area 
that affect model selection, for example, the unit of representation, are considered important (11, 12, 17, 19, 20). 
Other aspects in model construction that arise from the application of models to specific groups of patients or 
specific settings, include the scope of the model, the model perspective, choice of model type, choice of utility 
structure (e.g. quality adjusted utility scale) and the interventions to be included in the model (10-12, 17, 19, 
20). These guidelines identify the characteristics of individuals as a key element aiding the process of model 
selection, i.e., whether a model needs to represent individuals or groups or interactions between individuals (19). 
Furthermore, guidelines recommend that ‘the appropriate model type is determined by purpose, level of detail 
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and complexity’ (p.809); (19) and the use of ‘explicit processes’ involving expert consultation, influence 
diagrams or similar should be used to convert the conceptualization of the problem into an appropriate model 
structure (19).  
 
ISPOR-SMDM (14-20) recognised the difficulty for all models in achieving all the recommended best practice 
for model validation, i.e., face validity, internal validity, cross validity, external validity and predictive validity. 
Instead of establishing a minimum quality standard, guidelines recommend the adoption of optimal practices 
that all models should aim for (16). Among these, model transparency was identified as a key area of optimal 
practice that should be achieved by all models and is reflected by providing clear information on how the model 
was built, i.e., describing its structure, parameter values, and assumptions (16).  
 
ISPOR-SMDM (14-20) reiterated statements of good practice emphasizing on its appropriate conduct and 
furthermore establishing grounds for usage, for example, the use of time horizons sufficiently large to capture 
all health effects and costs relevant to the decision problem in cohort simulations; (14-20) or insisting on the 
value of model simplicity as long as a model’s face validity is not compromised (19). 
 
3.2. Model structure 
 
Good practice for selecting a model or the use of alternative model structures was discussed in ISPOR-SMDM 
(15, 17, 19) and in four out of 18 individual papers included in this review (21-24). Model structure should be 
considered in the initial stages in the process of model building (Table 2). Guidelines have suggested that prior 
to model building, researchers should identify: the problem and objective of the project; the analytical 
perspective of the model; the scope; the rationale for selecting the particular structure; the target population; the 
strategies and comparators; and then give justification for choosing the model type, the time horizon and the 
disease states (19, 21, 23, 24). These initial steps are important and will have important implications for the 
model structure, data requirements, and the reporting of the final results obtained from the model.  
 
Guidelines for conceptualizing a model’s structure have evolved from statements of general principles, for 
example by stating that the structure of a model should be consistent with the theory of the health condition and 
the available evidence (13), to more systematic processes describing how to select a model from competing 
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alternatives (21-24). ISPOR-SMDM (15, 17, 19) described the development and construction of a model as a 
process that starts with model conceptualization (19) which consists of a two-step process: problem 
conceptualization and model conceptualization. Problem conceptualization in this context is transforming 
knowledge of the healthcare process into a representation of the decision problem. Model conceptualization is 
the representation of the components of the problem using a particular decision-analytic method (Table 2). The 
nature of the problem and the project objectives are decisive in selecting the structure of a model. Furthermore, 
ISPOR-SMDM (15, 17, 19) suggested that the early specification of the decision problem and project objectives 
will improve model-building and the structure of the model (data requirements, analytic strategy and reporting) 
(19).  
 
The importance of the choice of model structure stems from the fact that alternative model structures can impact 
on model results and thereby affect decision making (19, 21, 23). The appropriate model type should be 
determined according to its purpose, level of detail required, and complexity (19). As previously demonstrated, 
guidelines aid the selection of an appropriate modelling approach by providing an overview of competing 
approaches and highlighting examples of where each alternative technique should be employed (19, 21, 23). The 
most common issues affecting a model’s selection are (15, 17, 19): 1) the unit of representation, does a model 
represent individuals or groups? The unit of representation affects the level of detail required for the variables 
that predict outcomes (19); 2) if the decision problem requires the modelling of the effect of an intervention on 
disease spread or use of limited resources, in other words, if interactions among individuals need to be 
represented then models designed for patient interactions are necessary (19); and 3) the time horizon is dictated 
by the problem scope. For example, decision trees are considered appropriate for models with very short time 
horizons, while longer horizons require the use of models such as State-Transition (for example a Markov) or 
Discrete Event Simulation DES (19). 
  
Among the most difficult stages in the conceptualization of a model is the selection of the appropriate level of 
model complexity, as very simple models may lose face validity if they do not incorporate all the aspects that 
experts feel are required; whereas complex models may be difficult to build, debug, analyse, understand and 
communicate (19). Guidelines have generally supported the choice of simpler models as ‘model simplicity is 
desirable for transparency, ease of analysis, validation and description’ (19), while at the same time it is 
recognised that under certain circumstances, more complex models may be needed. Consensus-based guidelines 
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stating common grounds for the application of more complex model structures have been developed, i.e., State-
transition models, DES and Dynamic Transmission models (17, 18, 20).  
 
3.3. Model uncertainty and synthesis of information 
 
ISPOR-SMDM (14) and an additional eleven individual papers (25-35) provided methodological guidelines for 
the analysis of model uncertainty (methodological, structural, parameter, heterogeneity and stochastic), and the 
use of sensitivity analysis. Step by step guidelines and checklists have been developed (Table 3) to aid 
researchers in accounting for uncertainty or to identify how uncertainty was incorporated in a model or to 
address special model circumstances, for example where the evidence is insufficient to give a clear 
representation of the uncertainty through parameter distributions (14, 26). The view presented by some of the 
studies included in this review is that many published models still fail to account correctly for the major sources 
of uncertainty, in particular structural uncertainty, indicating that a gap may still exist between techniques, 
guidelines, and what is done in practice (26, 31).  
 
Assumptions adopted in decision models determine its final structure and can consider: the choice of relevant 
comparators and health states, or available clinical evidence that determines the type of adverse events, duration 
of treatment effects, time dependency of probabilities and prognostic implications of surrogate end points or the 
clinical events included (14). Structural uncertainties arise when these structural assumptions are not formally 
quantified and it is uncertain whether they accurately reflect reality (14). Current methods for addressing 
structural uncertainty include scenario analysis (presenting the results under different model structures); model 
averaging (presenting results of different models using different assumptions and an average across these 
models); parameterization of structural uncertainty; and in the absence of data or presence of weak data, expert 
elicitation to translate expert beliefs into probability distributions (30). Model structure plays an important role 
in defining the relationship between inputs and outputs to the point that it has been recognised that structural 
uncertainty may be at least as important, in terms of its impact on results, as parameter uncertainty (14). ISPOR-
SMDM (14) highlighted the emerging interest in calibration methods as an aid to ensure consistency of inputs 
and outputs in a model. Calibration is used when data are available to match model outputs rather than model 
inputs: it is then necessary to determine parameter values which give model results that match the data (14).  
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Many techniques have been developed and have evolved which aim to capture the various sources of DAM 
uncertainty. However, there still remain some areas where more research is needed, such as: accounting for 
uncertainty surrounding quality of evidence for particular structural aspects; generalizability from one setting to 
another; and the way multiple sources of evidence should be combined (heterogeneity of parameter values from 
different sources) (26). ISPOR-SMDM (14) proposed the parameterization of structural uncertainties into a 
model as an approach to deal with issues around the quality of evidence, however this approach seems to 
become complex if a complete redesign/rebuilding of the model is required (nested structures). (14). Under 
these circumstances guidelines have stated that ‘where it is impossible to perform structural uncertainty analysis, 
it is important to be aware that this uncertainty may be at least as important as parameter uncertainty and 
analysts are encourage to be explicit about the structural assumptions that might impact their findings and 
suggest alternative assumptions for future modelling exercises (14).  
 
3.4. Model transparency and validation 
 
Four papers discussed methods to assess the consistency or validity of models and model transparency, (Table 
4) (16, 36-38). Model transparency reflects the extent to which a model’s structure, equations, parameter values 
and assumptions can be reviewed, and a model is considered transparent if any interested reader with the 
necessary expertise who wants to evaluate the model is able to reproduce it (16). Model validation has been 
recommended to enhance the credibility of models and as an indicator of reliability in practice guidelines (9, 16, 
36-38). Model transparency does not equal the accuracy of a model in making relevant predictions; a transparent 
model may yield the wrong answer, and vice versa, while a model may be correct and lack transparency. Thus, 
transparency and validation are both necessary for good practice in modelling (16). 
 
Validation involves a set of methods for judging the accuracy of models when making predictions. More recent 
guidelines have used the terms ‘model consistency’ or ‘model validation’ to refer to five types of model validity: 
face validity (evaluation of model structure, data sources, assumptions and results), internal validity (the 
practical model should behave as the theoretical model predicts), cross validity (comparison of results with other 
models), external validity (comparing model results and real-world results) and predictive validity (comparing 
model results with prospective observed events) (9, 16).  
 
A systematic review of guidelines in DAM 
 
12 
 
Principles and methods to enable researchers to assess model validity have been discussed and in some cases 
demonstrated (16, 37, 38). However, results of a study (38) established that health economic models based on 
limited follow-up data from one source may not be generalizable either to longer follow-up periods or other 
contexts. Furthermore, in addition to the standard considerations of uncertainty about parameter estimates, it is 
also important to assess the implications of model uncertainty on results, in other words, to undertake 
independent model validation (16). 
 
Best practice recommends that face validity (due to its subjective nature) should be judged by people who have 
expertise in the problem area, but who are impartial and preferably blinded to the results (16). Internal validity 
verifies that mathematical calculations are performed correctly and are consistent with the specification of the 
model. Methods to assess internal validity will depend on the model’s complexity, but two main stages of 
internal validity involve the verification of individual equations and their accurate implementation. It should be 
noted that internal validity does not evaluate the accuracy of model’s predictions (16). Cross validity involves 
examining different models and comparing their results to then identify and analyse the causes of differences 
and similarities in these results. External validation compares the results of a model with actual data however 
the difficulty in identifying ‘alternative data’ has been noted. Best practice to undertake external validation 
recommends following a formal process to compare a model’s results to actual event data. Guidelines provide 
awareness of the important limitation that external validation can only address the parts covered by data sources 
(16). Predictive validity remains a highly desirable type of independent model validation due to its potential 
ability to demonstrate the accuracy of the results obtained from the DAM. However its results are potentially 
limited if there are changes in the design of the study or other factors outside the control of the study design 
change during the development of the study (16). 
 
Even though the latest guidelines (16) have provided more detailed guidance on how best to ensure model 
transparency and undertake validity checks, which reflect the value of concise reporting of a model and 
advocate the quantification of uncertainties arising from differences in assumptions, (16) some quandaries seem 
to prevail. For example, in order to examine external validity, modellers are advised to use actual event data. 
However, that same data in many instances would already have been used to parameterise the model – as 
guidelines suggest that the most representative data sources should be used in developing a model. 
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Discussion  
 
This review has critically compared statements of good practice in contemporary guidelines and identified areas 
where further work may be needed. This review found: 1) good practice guidelines have been developed and 
agreed; adherence to these guidelines is considered as best practice in DAM; 2) guidelines should be seen as 
tools that if followed will lead to the results obtained being more credible; 3) common grounds in the 
application of guidelines; and 4) some aspects of the guidelines related to DAM require further development, for 
example, the choice of model structure, assessment of structural uncertainty and achieving predictive validity. 
 
Common grounds have been identified for the application of guidelines in aspects such as the specification of a 
model’s structure, the inclusion of incident cases over the time horizon of an evaluation, the use of time 
horizons, parsimonious model structure, and subgroup analysis in DAM. 
 
Most decision problems can be conceptualized using one of the available model types, whilst the choice of 
model structure is unlimited. There is general acceptance of the special circumstances under which complex 
modelling needs to be taken into consideration, while at the same time, overly complex models should be 
avoided if a simpler model can accurately reflect all aspects of the decision problem. More research should be 
undertaken of case studies comparing the economic efficiency of simple versus complex models, the use of 
hybrid models which are considered to be very flexible and accurate with no restriction on how time is handled 
(15), and the trade-off between model complexities versus model transparency. This should be done in light of 
the advances in computing that make complex calculations feasible and economically efficient, opening the way 
for the more generalised use of individual-based simulations (15).  
 
Whether model structure should be informed by data availability or not remains another conflicting aspect in 
DAM. Current guidelines have argued the case for building a model first and then looking for the data to 
populate it, as this strategy will result in more appropriate and relevant model structures (19). However an 
apparent drawback of this approach which has already been argued by detractors is data availability. 
Alternatively, finding the data to populate the model might be possible perhaps by adopting more assumptions 
based on expert opinion (15, 19). Independent of the assumptions adopted, the model parameters should reflect 
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the uncertainty due to the gaps in the available data, which in an ideal world would trigger the need for value of 
information analyses to show the value of this required data (14). 
 
Structural uncertainty remains an area of controversy; an inappropriate structure can invalidate the conclusions 
drawn from CE analyses, while choices made when structuring a model can significantly affect its results and 
the inferences from it. Until recently, even the definition of structural uncertainty was a matter of dispute; (27, 
30) however contemporary guidelines have clarified this concept by using an analogy with linear regression, and 
it is now recommended as good practice to factor in structural uncertainties into a model (14). 
 
Another area where issues have been raised has been with model validity. Guidelines have recognised that ‘not 
all models will be able to achieve all these best practices’ (14) while the ‘inability to do so does not necessarily 
imply a model is not useful’ (14). However recent guidelines seem to have provided a scope for analysts to use 
their own discretion to solve some issues, provided that the use of ‘optimal practices’, as described by methods 
and recommended practice is demonstrated (14). Some aspects of model generalizability demand further 
research because it relies on the availability of follow-up data ideally from the same source, and follow-up data 
from other sources may not be generalizable to longer follow-up periods or to new contexts (38). 
 
There are some areas where there is a contradiction between the guidelines; however we believe that as with 
model validity, these issues can be solved at the discretion of analysts. A good example is when guidelines 
indicate the use of all feasible and practical comparators (5, 19). The same guidelines indicate that the choice of 
comparators is governed by the scope of the model, which is a direct consequence of the research question. In 
other words, even though a broad range of feasible strategies may be available, the choice of comparators is 
expected to answer to the decision problem. However, the inclusion or exclusion of potentially relevant 
comparators should be assessed as part of the structural uncertainty of the model (27). 
 
This review has found that while guidelines have been developed and are available to aid researchers to inform 
the results of their studies and most importantly, to increase the credibility of their results, these guidelines lack 
practicality due to the extensive amount of information available and its complexity. Current standards of 
reporting could be improved if a single, comprehensive, user friendly and practical instrument is made available 
to direct researchers towards the key elements of good research practice in DAM which should be assessed and 
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reported to increase the credibility of their results. We aim to contribute towards this end by proposing a 
practical five-dimension framework to assess adherence to guidelines in DAM.  
 
The framework we propose incorporates and reflects much of the evidence from this review, i.e. it has 
synthesized all contemporary guidelines in a checklist instrument. To ensure its consistency, we adopted the 
most up to date and agreed guideline statement when components in each dimension were superseded or 
contradictory. The framework uses the following five-dimension checklist: i) problem concept; ii) model 
concept; iii) synthesis of evidence; iv) analysis of uncertainty; and v) model transparency and validation (see 
table 5). This framework does not attempt to replace the guidelines provided by ISPOR-SMDM 2012 or any 
other contemporary guidelines; instead it attempts to serve as a reference point for the thorough consultation of 
good practice guidelines.  
 
Strengths and limitations 
This study constitutes a comprehensive review of more than a decade of developments in DAM, including the 
most contemporaneous guidelines. While this study has discussed all available general guidelines in a single 
document, the breadth of this field determined that this review focus on aspects that are considered general to all 
models (model structure, model conceptualization, model parameters, model uncertainty and model 
transparency and validation). The exclusion criteria adopted (abstracts, posters, conference papers and non-
English language studies) may be considered as a limitation of this review, however these were required to 
guarantee consistency in the analysis; furthermore, a negligible number of non-English language studies were 
identified pertaining to applied studies. Some databases such as HEED, Psychinfo and Cinhal were not included 
in this review mainly because we took the view that the same references would be identified in Medline or their 
focus was applied research. This review does not address the choice of data and its processing to yield suitable 
inputs for the model; we took the view that this is a topic has been extensively developed in other fields such as 
epidemiology or statistics. Finally, as stated in the previous section, this review has excluded applied studies that 
are important for identifying which elements of guidelines pose greater challenges for analysts or correspond to 
deviances from guidelines in current practice. This undoubtedly triggers the need for future research on the 
adherence of current practice to guidelines and its impact on results of decision-modelling emphasizing for 
example, on issues around the reporting of uncertainty analysis or the assessment of structural uncertainty or 
around areas of increasing interest such as the practical use and feasibility of generic models.  
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4. Conclusions 
The framework to judge the adequacy of decision-modelling has changed dramatically since it was first 
envisioned; ISPOR-SMDM constitutes the most contemporaneous, up-to date and agreed set of good practice 
guidelines.  
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Table 1   General Guidelines  
Paper ID Model Structure 
Author(s) / 
year 
Topic Statement of 
Decision 
problem/objective 
Scope / 
analytic 
perspective 
Rationale 
for 
structure 
Strategies 
and 
comparators 
Model 
type 
Time 
horizon 
Disease 
states / 
pathways 
/ time to 
events 
Cycle 
length 
Parsimony 
Sonnenberg et 
al, 1994 [11]  
Framework to 
judge adequacy 
      
  

Sculpher M et 
al, 2000 [10]  
Framework for 
validity and 
quality 

  
 
  
  
  
Soto J, 2002 
[12]  
Checklist for 
decision-analytic  
      
      
Weinstein MC 
et al, 2003 
[13]  
Good modelling 
practice 
  
 
    
   
Philips Z et al, 
2004 [5] 
General 
guidelines  
        
Philips Z et al, 
2006 [9]  
Framework for 
quality 
assessment 
          
HTA, Canada, 
2006 [6]  
General 
guidelines in 
Canada  
 
  
  
      
Karnon J et al, 
2007 [8]  
Modelling issues     
      

    

Earnshaw J et 
al,  2008 [7]  
Guidelines for 
economic 
evaluation   
  
    

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ISPOR-SMDM, 
2012 [14-20]  
Good research 
practices 
              
Note: Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines 
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Table 1   General Guidelines (continuation) 
 
Paper ID Identifying and synthesizing evidence 
Author(s) / year Topic 
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Sonnenberg et al, 1994 
[11]  
Framework                       
Sculpher M et al, 2000 
[10]  
Framework                            
Soto J, 2002 [12]  Checklist                     
Weinstein MC et al, 2003 
[13]  
Good modelling practice                         
Philips Z et al, 2004 [5] General guidelines                 
Philips Z et al, 2006 [9]  Framework                  
HTA, Canada, 2006 [6]  General guidelines                       
Karnon J et al, 2007 [8]  Modelling issues                            
Earnshaw J et al,  2008 [7]  Guidelines                        
ISPOR-SMDM, 2012 [14-
20]  
Good research practices                         
Note: Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines 
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Table 1   General Guidelines (continuation) 
Paper ID Model validity 
Author(s) / year Topic Face/Internal/technical 
validity, verification or 
consistency 
Cross validity  External 
validation 
Predictive 
validation 
Sonnenberg et al, 1994 
[11]  
Framework to judge 
adequacy 

      
Sculpher M et al, 2000 
[10]  
Framework for validity 
and quality 
 
    
Soto J, 2002 [12]  Checklist for decision-
analytic modelling 
    

  
Weinstein MC et al, 
2003 [13]  
Methodology regarded as 
good modelling practice 
   
Philips Z et al, 2004 [5] General guidelines  
  
 
Philips Z et al, 2006 [9]  Framework for quality 
assessment 
     
HTA, Canada, 2006 [6]  General guidelines in 
Canada          
Karnon J et al, 2007 [8]  Modelling issues 
        
Earnshaw J et al,  2008 
[7]  
Guidelines for economic 
evaluation 

      
ISPOR-SMDM, 2012 [14-
20]  
Good research practices     
Note: Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines 
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Table 2   Model Structure  
Author(s) 
and year 
Area of 
guidelines 
Criteria for selecting a 
modelling approach 
Rationale for 
structure  
Model-based evaluation Parsimony Key recommendations  
Roberts 
(ISPOR_12) 
[19]  
Choice of 
model 
structure 
Justified in line with 
policy context and 
aiming to inform 
resource allocation  
Whether a model 
represents 
individuals or 
groups or 
interactions 
between 
individuals 
Expert consultation and 
conceptualization in two stages: 
problem conceptualization and model 
conceptualization  
Model simplicity 
however preserving 
face validity  
Early specification of the 
decision problem, modelling 
objectives and valuing outcomes 
will improve model efficiency 
(expert consultation, influence 
diagrams, concept mapping) 
Siebert 
(ISPOR_12) 
[20]  
Structures 
and model 
complexity 
Whether decision-
problem requires 
time-dependent 
parameters or time to 
an event or repeated 
events 
Markov models 
can handle 
memory by 
creating states 
that include 
history; but then 
model complexity 
STM are comprehensive and powerful 
tools to guide decision in health care 
Decision tree has 
limited ability to 
reflect time; then 
STM seems the 
simplest option 
Markov model if decision 
problem has a manageable 
number of health states; if not, 
use a individual-level state-
transition model (STM) 
Karnon 
(ISPOR_12) 
[17]  
Structures 
and model 
complexity 
DES justified on 
model flexibility 
Constraint 
resources; 
patient's 
interactions; time 
dependencies 
Value of DES to inform health care 
decisions; flexible and able to 
represent complex behaviour and 
interactions between individuals 
Easy representation 
of complex systems 
A good choice if individuals are 
subject to multiple or competing 
risks 
Bentley TG 
et al, 2010 
[22]  
Structures 
and model 
complexity 
Subsequent event risk 
dependent on prior 
event history; 
simulation of event or 
disease risks over 
time; improving 
validity 
Recurrent events 
and time 
dependency 
The ability of incorporate past history 
is restricted to the number of model 
health states 
Trade-off between 
model bias and 
model complexity 
Failing to incorporate prior event 
history in Markov models would 
overestimate the impact of an 
intervention; incorporate 
dependency by adding states 
that track event history; make 
subsequent event risks 
dependent on this history 
Brennan A 
et al, 2006 
[23]  
Choice of 
model 
structure 
Needs to be justified 
Interactions 
between 
individuals or an 
individual level 
model; choice 
Comparison of health technologies 
and synthesising evidence on costs 
and benefits 
Simplest model 
that addresses 
objectives and 
structure of disease 
and treatment 
Responsibility of developers to 
select the most appropriate 
modelling approach; taxonomy 
grid is a guidance  
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from taxonomy of 
model structures 
Barton P 
et al, 2004 
[21]  
Choice of 
model 
structure 
Needs to be justified 
Interactions 
versus not 
interactions 
between 
individuals 
Two distinct and independent 
aspects: mean estimate of cost-
effectiveness and exploration of 
uncertainty in the model inputs 
Simplicity (relates 
to the size of the 
model) is seen as 
an advantage 
Check dependence or 
independence among 
individuals; model simplicity is 
an advantage; model validation; 
challenge the need for a 
complex model 
Karnon J, 
2003 [24]  
Structures 
and model 
complexity 
Assess relative 
advantages of 
alternatives according 
to areas of treatment 
Model flexibility 
and analytic input 
(complexity of 
model building) 
Choice depend on flexibility vs. time 
availability; there may be 
circumstances where DES provides a 
more accurate representation of the 
data 
A simpler model 
was the optimal 
technique as 
compared to a 
complex DES model 
Results of different models 
(Markov or DES) may produce 
likely results; model flexibility 
(DES) may be outweighed by 
greater time required to 
evaluate its results 
Note: DES= Discrete Event Simulation; STM= State Transition Model
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Table 3   Model Uncertainty & Synthesizing Evidence 
Author(s) / 
year 
Area of 
guideline 
General principles Way of reporting Methodological issues Methods /recommendations 
Briggs 
(ISPOR_12) 
[14]  
Point 
estimate(s) & 
parameter 
uncertainty  
Responsible reporting; use of 
terminology; justify its 
omission; decision maker’s 
role; preferable parameterize 
uncertainty from structural 
assumptions if possible 
Use tornado diagrams, threshold 
plots, or statements of threshold 
parameter to report DSA; 
describe assumption(s); report 
uncertainty around calibrated 
parameter(s); report EVPI if 
needed 
Methodological, structural, 
patient heterogeneity; parameter 
uncertainty and stochastic 
uncertainty 
For structural uncertainty, 
calibration approaches; for 
parameter uncertainty  DSA or 
PSA; for point and interval 
estimates use CI or distributions; 
reflect absence of evidence 
Bilcke J et 
al, 2011 
[26]  
Uncertainty: 
Step-by-step 
guide and 
checklist   
Formulate decision-problem; 
specify sources of uncertainty; 
obtain information and 
evidence; report results; 
apportion uncertainty to 
sources 
Report choices of normative 
approach(es); present sources of 
uncertainty; use distributions; 
assess the most influential 
sources of uncertainty; report 
results of PSA 
Methodological, structural and 
parameter uncertainty 
State if there are more than one 
approach that can be used; use 
distributions; assess the most 
influential sources of uncertainty; 
global sensitivity analysis; PSA  
Jain R et 
al, 2011 
[31]  
Sensitivity 
Analysis  
Report all sources of 
uncertainty; Strengths and 
limitations of SA should be 
acknowledge (interactions and 
correlations between 
parameters) 
If long term analysis is needed, 
conduct CEA under various time 
horizons; use for instance, 
tornado diagrams, or threshold 
analysis to present results 
Methodological, structural, 
parameter 
Model averaging and 
parameterization for structural 
uncertainty; methodological 
uncertainty can be addressed by 
providing results for a 'reference 
case'; DSA or PSA.  
Koerkamp 
BG et al, 
2010 [32]  
Uncertainty 
and patient 
heterogeneity 
Consider range of assumptions 
for the natural course of a 
disease; provide model for 
every set of assumptions 
instead of using the single best 
model; trade-off between the 
realism of a model and time 
availability  
Use tornado diagrams or 
threshold plots; describe 
assumption(s); report 
uncertainty; if the purpose of the 
PSA is the acquisition of 
information to reduce 
uncertainty, report EVPI 
Parameter uncertainty, patient 
heterogeneity, stochastic 
uncertainty (first-order 
uncertainty) 
PSA joint uncertainty; 
parameterization model 
structure uncertainty; first-order 
Monte Carlo analysis for 
stochastic; DSA for parameter 
uncertainty; EVPI if needed 
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Jackson CH 
et al, 2011 
[30]  
Structural 
uncertainty 
Various sources: statistical 
models, evidence used, states 
or clinical events represented, 
or treatment strategies 
considered 
Should be acknowledge, assess 
and reported 
Structural uncertainty 
Reference case model; assign 
distributions; use PSA; for non-
parametised uncertainties use 
global model; if lack of data, elicit 
distributions 
Strong M 
et al, 2010 
[35]  
How complex 
a model 
should be 
Uncertainty in model structure 
is complex; it involves making 
judgements about model's 
ability to accurately represent 
a decision problem  
Most commonly by PSA, however 
it will only quantify uncertainty 
about the costs and 
consequences; problem when a 
model lacks accuracy 
Uncertainty about the model 
input values and model structure 
To properly represent 
uncertainty about the costs and 
outcomes, structural uncertainty 
must be presented; structural 
uncertainty measured with 
model averaging or the 
discrepancy approach 
Bojke L et 
al, 2009 
[27]  
Structural 
uncertainty 
Impossible to accurately 
predict mean costs and 
outcomes; sources are 
treatment effects and type of 
model 
Importance of differentiating 
parameter and structural 
uncertainty: if uncertainty can be 
parameterised, then there is 
parameter uncertainty 
Parameter, methodological and 
structural (little attention given 
to structural uncertainty) 
Model selection (not plausible); 
model averaging (difficulty 
determining posterior 
distributions); parameterising 
(directly representing uncertainty 
by adding other 'uncertain' 
parameters) 
Briggs AH 
et al, 2003 
[28]  
Probabilistic 
probabilities 
over multiple 
branches 
If there is a need to specify a 
distribution over multiple 
branches at a chance node 
Have the Dirichlet distribution 
specified over multiple branches 
at a chance node 
Inconsistencies performing 
sensitivity analysis if a node has 
more than two branches and the 
sum of the branching 
probabilities is different from 1  
Use Dirichlet distribution, a 
multivariate equivalent of the 
beta distribution 
Kuntz KM 
et al, 2002 
[33]  
Patient 
heterogeneity 
Cohorts are defined based on 
population characteristics; 
sometimes other 
characteristics may be 
overlooked (disease incidence 
Heterogeneity bias may be 
evaluated as a function of 3 
parameters: annual probability of 
developing the disease; RR of 
disease with vs. without the 
The assumption that each health 
state contain a homogenous 
population group does not 
always hold: for instance, in 
presence of risk factors affecting 
Adjust by introducing an 
heterogeneity factor; probability 
of transitioning to disease 
dependent on heterogeneity 
factor; transition probabilities 
A systematic review of guidelines in DAM 
 
26 
 
or progression), causing 
heterogeneity  
factor; iii) baseline prevalence of 
the factor 
the chance of developing disease  averages to that of the model 
without adjustment 
Briggs AH 
et al, 1999 
[29]  
Uncertainty 
Study designs included were 
modelling-type based 
approaches 
The majority included some form 
of sensitivity analysis (one-way 
sensitivity analysis) 
Mainly one-way SA; 5% 
attempted statistical analysis; 
17% failed to provide any 
attempt to quantify uncertainty 
in their results 
Reference case (comparability of 
results); potential for ICER to 
vary; avoid selective comparison; 
uncertainty; interval estimates; 
SA; probabilistic nature of 
reported range;  descriptive 
statistics; estimate CI; present 
CEAC  
Andronis L 
et al, 2009 
[25]  
Sensitivity 
analysis 
DSA requires variables and 
sources to be justified; for PSA 
distributions should be placed 
around all parameters 
(excluded parameters should 
be justified) 
Repeated analysis should be run 
using different models and 
methods where uncertainties 
exist  
Methodological and structural 
uncertainty 
Univariate, multivariate, PSA and 
DSA; distributions in line with 
logical bounds; if correlation is 
expected, use joint distributions 
(do not assume independence) 
Sendi P et 
al, 2002 
[34]  
Uncertainty & 
opportunity 
costs 
Univariate and multivariate SA 
to assess robustness; however 
SA does not inform joint 
uncertainty  
Alternative approaches as a 
result of the intractability of the 
ICER: Net Health Benefit (NHB) 
and CEAC 
ICER difficulty apparent if a 
distribution extends over more 
than one quadrant 
NHB, however a problem if 
lambda is unknown; CEAC, 
however same problem with 
lambda; uncertainty can be 
accounted for using Bayesian 
methods 
Note: DSA= Deterministic Sensitivity analysis; PSA= Probabilistic Sensitivity Analysis; EVPI= Expected Value of Perfect Information; CI= Confidence Intervals; SA= Sensitivity 
Analysis; CEA= Cost-Effectiveness Analysis; RR= Risk Ratio; ICER= Incremental Cost-Effectiveness Ratio; CEAC= Cost-Effectiveness Acceptability Curve; NHB= Net Health 
Benefit 
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Table 4   Model Transparency and Validation 
Author(s) / 
year 
Area of 
guideline(s) 
Methodology 
Rationale for model 
transparency and validation  
Best practice  Recommendations  
Eddy 
(ISPOR_12) 
[16]  
Transparency 
and 
validation of 
models 
Recommendations 
on optimal 
practice 
Made available model’s non-
technical and technical 
documentation, written in 
sufficient detail to enable the 
reader to evaluate a model 
Face validity of a model's 
structure, evidence, problem 
formulation and results; 
transparency and validation  
Models are instruments to help decision makers 
answer complex questions; model confidence and 
credibility is demonstrated by clarity in model 
structure, equations, parameters, and 
assumptions, and by subjecting models to tests of 
validity 
Karnon J, 
2011 [37]  
Model 
validation 
Empirical 
comparison 
Identification of input 
parameter(s) that produce 
output that best predict 
observed data 
Probabilistic calibration of 
models produced 
improvements in model's 
accuracy, and reduced 
uncertainty 
Widespread of model calibration (probabilistic 
calibration); a process of validation against more 
theoretically grounded approaches is valuable 
(Bayesian updating approach) 
Goldhaber-
Fiebert JD, 
2010 [36]  
External 
model 
validation 
Literature review  
Comparing model to 
independent data not used in 
the model 
Heterogeneity in how results of 
model evaluation are reported 
Evaluation via comparison(s) to independent 
studies; structured reporting format: empirical 
study description, baseline characteristics, study 
protocol, study outcomes, model outcomes and 
model consistency  
Kim LG, 
2010 [38]  
Model 
validation 
Use of internal, 
prospective and 
external validation 
Indication of reliability of 
assumptions adopted  
A model should be generated 
which fits all available data  
Model based on limited data may not be 
generalizable; uncertainty from model 
assumptions as important as parameter 
uncertainty; new model should be generated 
which fits all available data; model validation 
should assess: key events, rate of accrual of events 
and absolute and incremental costs and effects 
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Table 5 Framework to assess adherence to good practice guidelines in Decision-Analytic modelling (DAM) 
DIMENSION 1: PROBLEM CONCEPT 
Components of 
good practice 
Questions for review 
Yes , No, 
or NA 
Attributes 
Decision 
problem  
Is there a written statement of the decision problem 
and scope of the study?    
A clear statement of the decision problem and scope would determine the interventions and health outcomes 
to be measured 
Are the objective(s) of the study and model structure 
consistent with the stated decision problem and scope?   
They are expected to be consistent 
 
Analytical 
perspective 
Has the perspective of the model been stated?   Most common perspectives are: patient, health system (insurer) and society 
Target 
population 
Has the target population been identified?   
Target population should be defined in terms of features relevant to the decision (geography, patient 
characteristics, including comorbid conditions, disease prevalence and stage) 
Health 
outcomes 
Are the outcomes of the model stated and consistent 
with the perspective, scope and overall objective(s) of 
the model?  
  
Health outcomes may be events, cases of disease, deaths, life-years gained, quality-adjusted life-years, 
disability-adjusted life-years or other measures important to stakeholders and should be directly relevant to 
the question being asked 
Has any adverse effect of the intervention(s) been 
captured?   
Interventions may cause negative health consequences that need to be modelled and discussed as part of the 
study's results. The impact of assumptions regarding adverse effects of interventions should be assessed as 
part of the structural uncertainty analysis 
Comparators 
Is there a clear definition of the alternative 
interventions under evaluation?   
Usually the choice of comparators is governed by the scope of the model. Impact of assumptions adopted 
when deciding upon comparators should be assessed as part of the structural uncertainty analysis 
Is there a discussion around feasible options or 
justification for the exclusion of feasible options?   
The choice of comparators affects results and should be determined by the decision problem, not by data 
availability. All feasible and practical strategies as determined by the scope of the model should be considered. 
Constraining the range of strategies should be justified 
Time horizon 
Is the time horizon of the model justified and sufficient 
to reflect all important differences between options?   
Time horizon of the model should be long enough to capture relevant differences in outcomes across strategies 
(lifetime). Time horizon is dictated by the problem scope 
 Note: NA= Not Apply 
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DIMENSION 2: MODEL CONCEPT 
Components of 
good practice 
Questions for review 
Yes , No, 
or NA 
Attributes 
Choice of 
model type 
Has the unit of representation been given?    
Usually stated in terms of groups or individuals. If groups are being modelled most frequently decision trees, Markov 
processes or infectious disease models are the correct choice; if individuals are being modelled then the choice is between 
DES, dynamic transmission models or agent-based models 
Is there a need to model the interaction 
between individuals in this model? Has this 
been discussed? 
  
If interactions between individuals is required (when the disease or treatment includes interactions between individuals) 
then DES, dynamic-transmission, or agent-based models may be the correct choice 
Does the decision problem require a short 
time horizon?   
For simple models or problems (short time horizon, few outcomes) a decision tree may be appropriate; time horizon should 
be large enough to capture all health effects and costs directed related to the decision problem 
Is it necessary to model time in discrete 
cycles?    
Continuously for Individual STM  or in discrete cycles for Markov STM;  if the assumption that transition probabilities do not 
depend on history is not required, then individual state-transition models are an alternative; If disease or treatment process 
need to be represented as health states, state transition models are appropriate (Markov type) 
Is there a need to model competition for 
resources or the development of waiting 
lists or queues? 
  
 If the problem requires the ability of a model to incorporate interactions between individuals and other model parts for 
example to answer questions on resource allocation i.e., organ allocation for transplantation, distribution of antiretroviral 
medications in resource-poor environments, then a DES may be appropriate 
Has a type of model been chosen and 
discussed?     It is expected that studies report on the reasons for choosing a type of model 
Model 
structure 
Has the starting cohort been defined by 
demographic and clinical characteristics 
affecting the transition probabilities or state 
values?  
  If results may vary by subgroups (age, sex, risk factors) is advisable to report results for different cohorts 
Has health states and transitions reflecting 
the biological/theoretical understanding of 
the disease or condition been modelled? 
  
States should adequately capture the type of intervention (prevention, screening, diagnostics, and treatment) as well as the 
intervention's benefits and harms. States need to be homogeneous with respect to both observed and unobserved 
characteristics that affect transition probabilities 
Note: NA= Not Apply 
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DIMENSION 3: SYNTHESIS OF EVIDENCE 
Components of 
good practice 
Questions for review 
Yes , 
No, or 
NA 
Attributes 
Data sources 
Has transition probabilities and intervention effects 
been derived from representative data sources for the 
decision problem? 
  Most common sources of data include population-based epidemiological studies, control arms of trials or literature 
Has (all) methods and assumptions used to derive 
transition probabilities and intervention effects been 
described/justified? 
  
Attention should be given to the use of transition probabilities and rates; conversion of transition probabilities from 
one time unit to another should be done through rates and never presented as percentages 
Has parameters relating to the effectiveness of 
interventions derived from observational studies been 
controlled for confounding?  
  
If results of meta-analyses were used as data sources then consider how potential confounders are addressed; 
consider the likelihood of increased heterogeneity resulting from residual confounding and from other biases 
across studies. Efficacy derived from RCT may have to be adjusted for compliance to reflect real-world 
effectiveness. Effectiveness derived from observational studies must be adjusted for confounding (e.g., using 
multivariate regression techniques or propensity scoring). Adjustment for time-varying confounding (confounders 
that simultaneously act as intermediate steps in the pathway between intervention and outcome) require special 
methods such as marginal structural analysis or g-estimation. When results from observational studies are used in 
the model, causal graphs can be used to explicitly state causal assumptions 
Has the quality of the data been assessed 
appropriately?   Sources of data and data limitations are expected to be discussed 
Has expert opinion been used, are the methods 
described and justified?   An expectation that strengths and limitations of assumptions adopted should be included 
Utilities  
Are the utilities incorporated into the model 
appropriate?    
methods used to obtain utility weights and methodology used to transform health estate estimates into quality of 
life scores 
Is the source for the utility weights referenced?   Sources of data and data limitations are expected to be discussed 
Cycle length 
and half cycle 
correction 
Has the choice of cycle length been justified?   It should be based on the clinical problem and remaining life expectancy 
Has the use of a half cycle correction been stated?   Any assumption adopted is expected to be disclosed 
Resources/ 
costs 
Are the costs incorporated into the model justified and 
sources described?   Sources of data and data limitations are expected to be discussed 
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Has discount rates been reported and justified given 
the target decision-maker?   
Patient 
heterogeneity  
Has patient heterogeneity been considered?   
For example, in a cohort model states need to be homogeneous to observed or unobserved characteristics 
affecting transition probabilities to observed or unobserved characteristics affecting transition probabilities 
Parameter 
precision 
Has mean values and distributions around the mean 
and the source and rationale for the supporting 
evidence been clearly described for each parameter 
included in the model? 
  Sources of data and data limitations are expected to be discussed 
Note: NA= Not Apply 
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DIMENSION 4: ANALYSIS OF MODEL UNCERTAINTY 
Components 
of good 
practice 
Questions for review 
Yes , No, 
or NA 
Attributes 
Uncertainty  
Has analyses of uncertainty pertaining to the 
decision problem been included and reported? If 
not, has the reasons been explained for its 
omission? 
  Analysis of uncertainty is expected to be include as part of the DAM 
Parameter 
estimation & 
uncertainty 
Has one-way DSA or two-way sensitivity analysis 
been performed?   
Tornado diagrams, threshold plots or simple statements of threshold parameter values, are all appropriate. Uncertainty 
of parameters may be represented by several discrete values, instead of a continuous range, called 'scenario analyses'. It 
is a good practice to include the specification of parameter’s point estimate and a 95% CI range.  
Has a Probabilistic Sensitivity Analysis (PSA) been 
included?   
The specific distribution (e.g. Beta, normal, lognormal) as well as its parameters should be disclosed. When PSA is 
performed without an accompanying EVPI, options for presenting results include CEAC and distributions of net monetary 
benefit or net health benefit. When more than two comparators are involved, curves for each comparator should be 
plotted on the same graph. 
Has correlation among parameters been 
assessed?   Lack of evidence on correlation among parameters should not lead to an assumption of independence among parameters 
If model calibration was used to derive 
parameters, has the uncertainty around 
calibrated values been tested using DSA or PSA?  
  
Calibration is commonly used to estimate parameters or adjust estimated values such as overall and disease specific 
mortality and event incidence rates 
Structural 
uncertainty 
Has a discussion about the inclusion/exclusion of 
assumptions affecting the structure of the model 
been included?  
  
For example: i) health states and the strategies adopted following the recurrence of events; ii) length of treatment 
effects; iii) types of adverse effects included; iv) duration of treatment effects; v) time dependency of probabilities (in a 
time dependent utility, the cost of delaying treatment as a function of the time a patient has remained in an untreated 
acute pathological state); vi) prognostic implications of surrogate end points or vii) clinical events. Although these 
structural assumptions are not typically quantified, it is uncertain whether they express reality accurately and for that 
reason they should be assessed as part of structural uncertainty analysis 
Other 
reporting of 
uncertainty 
analyses 
Has the EVPI being measured /discussed?   
If the purpose of a PSA is to guide decisions about acquisition of information to reduce uncertainty in the results, EVPI 
should be presented in terms of expected value of information. EVPI is commonly reported in monetary terms using net 
monetary benefit or net health benefits; EVPI should be reported for specified ICER thresholds 
Note: NA= Not Apply 
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DIMENSION 5: MODEL TRANSPARENCY AND VALIDATION 
Components of 
good practice 
Questions for review 
Yes , No, 
or NA 
Attributes 
Transparency  
Has a graphical description of the model been 
provided?     
Has all sources of funding and their role been 
identified?     
Has all methods used been customised to 
specific application(s) and settings?     
Has the report used nontechnical language and 
clear figures and tables to enhance the 
understanding of the model? 
  
  
Has limitations and strengths been 
acknowledged/discussed?     
Is there any reference as to whether technical 
documentation would be made available at 
request? 
  
  
Validation 
Is there any evidence of model’s face validity?   
Can occur in several ways: the group that develop the model can appeal to members of the modelling group, people in the 
same organisation who did not build the model, or external consultants. Any reader can perform his/her own evaluation. 
Peer review (previous to publication) 
Has internal validity been assessed?   
Verification or technical validity; models should be subject to rigorous verification and the methods used should be 
described and results made available on request 
Has cross-validation been assessed?   
or external consistency (involves examining different models that address the same problem and comparing their results) 
its meaningfulness depends on the degree to which methods and data are independent. Modellers should search for 
modelling analyses of the same or similar problems and discuss insights gained from similarities and differences in results 
Has external validity been assessed?    
This compares the model's results with actual event data; a formal process needs to be developed including identifying 
suitable sources of data; results of external validation should be made available 
Has the model’s predictive validity been 
assessed?   If feasible given the decision problem and future's sources availability 
Note: NA= Not Apply 
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SUPPLEMENTAL MATERIAL (for possible WEB publication) 
Appendix  
Table 1: Search results from MEDLINE AND EMBASE  
Steps Search criteria Number of hits 
1 (checklist$ or check list$ or standards or 
standardi?ation or peer review or rules or critiquin or 
criteria or good or bad or correct$ or bias or 
fundamentals recommend$ or best or strength$ or 
weakness$ or quality or qualities or validity or 
guideline$ or validation or checkpoint$ or critically 
appraise or problems or limitations or rating scale$ or 
framework$ or protocol$ or audit or principles or 
methodolog$ or validate or validation or evaluating or 
properties or guidance or integrity or evaluation or pros 
or cons).m_titl. 
2261664 
2 limit 1 to abstracts 1470011 
3 limit 2 to English language 1266438 
4 limit 3 to yr="1990 -Current" 1052800 
5 limit 4 to humans 684348 
6 (economic model$ or Markov model$ or mathematical 
model$ or cost model$ or decision model$ or 
pharmacoeconomic$ model$ or decision tree$ or 
decision data or decision analytic$ or decision analysis 
or economic evaluation? or economic analysis).m_titl. 
30075 
7 limit 6 to abstracts 24245 
8 limit 7 to English language 21989 
9 limit 8 to yr="1990 -Current" 19501 
10 limit 9 to humans 12259 
11 5 and 10 3930 
12 remove duplicates from 11 2486 
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Table 2: Search results from Cochrane Library  
Steps Search criteria Number of hits 
1 economic model* or economic analysis* or economic 
evaluation* or decision analytic* or decision analysis* 
or economic study* or economic submission* from 
1990 to 2013, in Methods Studies, Technology 
Assessments and Economic Evaluations (Word 
variations have been searched) 
14677 
 
2 guideline* 13983 
3 #1 and #2 1664 
 
 
 
